Compare UTG & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTG | LIVN |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2003 | 2015 |
| Metric | UTG | LIVN |
|---|---|---|
| Price | $40.04 | $78.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $72.43 |
| AVG Volume (30 Days) | 260.4K | ★ 622.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | ★ N/A | $196.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.81 | $41.02 |
| 52 Week High | $43.90 | $85.27 |
| Indicator | UTG | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 43.69 |
| Support Level | $39.41 | $61.63 |
| Resistance Level | $41.55 | $80.96 |
| Average True Range (ATR) | 0.62 | 2.31 |
| MACD | 0.03 | -0.78 |
| Stochastic Oscillator | 35.11 | 27.67 |
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.